Prandin (Type 2 Diabetes) - Analysis and Forecasts to 2020

Description: Prandin (Type 2 Diabetes) – Analysis and Forecasts to 2020

Summary

GlobalData's pharmaceuticals report, “Prandin (Type 2 Diabetes) – Analysis and Forecasts to 2020” provides Prandin sales estimates for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Type 2 Diabetes market. This report is built using data and information sourced from GlobalData's proprietary databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

- Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
- Analysis and review of Prandin including historical sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Prandin including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales forecast for 2011-2020 for Prandin in the seven major markets

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug's performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Keywords

Prandin, Type 2 Diabetes, Diabetes, repaglinide, Sales forecast, meglitinide, Victoza, Onglyza, Januvia, Janumet, Lantus, Novo Nordisk

Contents:

1
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Diabetes
2.2 Epidemiology
2.2.1 Prevalence
2.2.2 Mortality
2.3 Etiology and Risk Factors
2.3.1 Obesity
2.3.2 Sedentary Lifestyle
2.3.3 Family History and Genetics
2.3.4 Ethnicity
2.3.5 Old Age
2.4 Economic Impact of Diabetes
2.5 GlobalData Report Guidance
3 Type 2 Diabetes: Market Characterization
3.1 Type 2 Diabetes Market
3.2 Type 2 Diabetes Market Forecasts
3.3 Type 2 Diabetes Market: Drivers and Restraints
3.3.1 Drivers
3.3.2 Restraints
4 Classification of Diabetes
4.1 Types of Diabetes
4.1.1 Type1 Diabetes
4.1.2 Type 2 Diabetes
4.1.3 Gestational Diabetes
4.2 Diabetes Complications
4.2.1 Cardiovascular Disease
4.2.2 Nephropathy
4.2.3 Neuropathy
4.2.4 Amputation
4.2.5 Retinopathy
5 Evolution of Anti-Diabetic Treatments
6 Medications
6.1 Insulin
6.2 Oral Medications
6.2.1 Sulfonylureas (SUR)
6.2.2 Biguanides (BGDs)
6.2.3 Alpha-Glucosidase Inhibitors (AGI)
6.2.4 Meglitinides
6.2.5 Thiazolidinediones (TZDs)
6.2.6 Dipeptidyl Peptidase IV (DPP-4) Inhibitors
6.2.7 Oral Combination Therapy
6.3 Other Injectionable Medications
6.3.1 Pramlintide
6.3.2 Exenatide
6.4 Market Share as per Classes in Type 2 Diabetes
7 Prandin
7.1 Introduction
7.2 Mechanism of Action
7.3 Clinical Studies
7.4 Approval of Prandin
7.5 Factors Affecting Sales of Prandin
7.5.1 Better Efficacy in Comparison with Starlix
7.5.2 Better Safety Profile
7.5.3 Low Intraclass Competition
7.5.4 First Mover Advantage
7.5.5 Launch of PrandiMet
7.5.6 Generic Entry in the European Region
7.5.7 New Treatment Options
7.6 Drug Evaluation
7.6.1 Drug Risk Benefit Score
7.6.2 Intensity of Competition
7.7 Sales Forecasts
7.7.1 Target Patient Pool for Prandin
7.7.2 Dosing
7.7.3 Market Penetration
7.7.4 Annual Cost of Therapy
7.7.5 Sales Projections of Prandin
8 Diabetes Market: Appendix
8.1 Market Definitions
8.2 List of Abberiviations
8.3 Research Methodology
8.3.1 Coverage
8.3.2 Secondary Research
8.3.3 Forecasting
8.3.4 Number of patients approved to take the drug
8.3.5 Net Penetration of Drug
8.3.6 Net Annual Dosing
8.3.7 Annual Cost of Therapy
8.4 Drug Sales Estimates Model
8.5 Contact Us
8.6 Disclaimer
8.7 Sources

1.1 List of Tables
Table 1: Diabetes, World, Prevalence Estimates for the age group 20-79 years (million), 2000-2030
Table 2: Diabetes, Top 10 Countries, by Prevalence (million), 2010 and 2030
Table 3: Diabetes, Top 10 Countries, Highest Health Expenditures ($bn), 2010
Table 4: Type 2 Diabetes, World, Major Marketed Drugs by sales ($m), 2010
Table 5: Type 2 Diabetes, World, Major Pipeline Products in Phase III clinical trials
Table 6: Diabetes, Worldwide, Prevalence Estimates, 2010 and 2030
Table 7: Overweight-, Global, Prevalence Estimates in Males Aged 15 and above (%), 2005
Table 8: Diabetes Drugs Evolution
Table 9: Prandin Efficacy as Monotherapy
Table 10: Prandin Efficacy in Combination with Metformin
Table 11: Prandin Efficacy in Combination with Rosiglitazone
Table 12: Drug Risk Benefit Score of Prandin
Table 13: Annual Cost of Therapy of Prandin, 2011
Table 14: Prandin, Type 2 Diabetes, Global, Sales Estimates ($m), 2002–2020
Table 15: Prandin, Type 2 Diabetes, The US, Sales Estimates ($mn), 2002–2020
Table 16: Prandin, Type 2 Diabetes, The UK, Sales Estimates ($mn), 2002–2020
Table 17: Prandin, Type 2 Diabetes, France, Sales Estimates ($m), 2002–2020
Table 18: Prandin, Type 2 Diabetes, Germany, Sales Estimates ($m), 2002–2020
Table 19: Prandin, Type 2 Diabetes, Italy, Sales Estimates ($m), 2002–2020
Table 20: Prandin, Type 2 Diabetes, Spain, Sales Estimates ($m), 2002–2020
Table 21: Prandin, Type 2 Diabetes, Japan, Sales Estimates ($m), 2011–2020

1.2 List of Figures
Figure 1: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (in %), 2010
Figure 2: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (in %), 2030
Figure 3: Diabetes, World, Mortality, 2010
Figure 4: Top 10 Causes of Mortality, Worldwide, 2008
Figure 5: Type 2 Diabetes, Global, Market Size Forecasts ($bn), 2010–2020
Figure 6: Mechanism of Action of Sulfonylureas
Figure 7: Mechanism of Action of Biguanide, Thiazolidinediones, Alpha-Glucosidase Inhibitors
Figure 8: Mechanism of Action of Metformin and Alpha-Glucosidase Inhibitors
Figure 9: Mechanism of Action of Thiazolidinediones
Figure 10: Mechanism of Action of DPP IV Inhibitors
Figure 11: Type 2 Diabetes, Global, Branded Market Share by Value, By Class (%), 2010
Figure 12: Prandin, Type 2 Diabetes, Global, Sales Estimates ($mn), 2002–2020
Figure 13: Prandin, Type 2 Diabetes, The US, Sales Estimates ($mn), 2002–2020
Figure 14: Prandin, Type 2 Diabetes, The UK, Sales Estimates ($m), 2002–2020
Figure 15: Prandin, Type 2 Diabetes, France, Sales Estimates ($mn), 2002–2020
Figure 16: Prandin, Type 2 Diabetes, Germany, Sales Estimates ($m), 2002–2020
Figure 17: Prandin, Type 2 Diabetes, Italy, Sales Estimates ($m), 2002–2020
Figure 18: Prandin, Type 2 Diabetes, Spain, Sales Estimates ($m), 2002–2020
Figure 19: Prandin, Type 2 Diabetes, Japan, Sales Estimates ($m), 2011–2020
Figure 20: Prandin, Type 2 Diabetes, Sales Distribution by Country (%), 2009
Figure 21: Patients Approved for the Drug

Ordering:
Order Online - http://www.researchandmarkets.com/reports/2075303/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Prandin (Type 2 Diabetes) - Analysis and Forecasts to 2020
Web Address: http://www.researchandmarkets.com/reports/2075303/
Office Code: SCD21WSV

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF)</td>
<td></td>
<td>USD 4000</td>
</tr>
<tr>
<td>Site License</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Electronic (PDF)</td>
<td></td>
<td>USD 2000</td>
</tr>
<tr>
<td>Single User</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Electronic (PDF)</td>
<td></td>
<td>USD 6000</td>
</tr>
<tr>
<td>Enterprisewide</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr  [ ] Mrs  [ ] Dr  [ ] Miss  [ ] Ms  [ ] Prof
First Name: ______________________  Last Name: ______________________
Email Address: * ______________________
Job Title: ______________________
Organisation: ______________________
Address: ______________________
City: ______________________
Postal / Zip Code: ______________________
Country: ______________________
Phone Number: ______________________
Fax Number: ______________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: __________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World